Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. (Q35230273)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. |
scientific article |
Statements
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial (English)
G Viale
M M Regan
P Dell'Orto
B B Rasmussen
G MacGrogan
J F Forbes
R J Paridaens
I Láng
B Thürlimann
H Mouridsen
L Mauriac
R D Gelber
K N Price
A Goldhirsch
B A Gusterson
A S Coates
BIG 1-98 Collaborative and International Breast Cancer Study Groups
18 February 2011
1 reference